Reporting on June 4, 2026, noted that phase 2 trial presented at ASCO annual conference shows that the personalized mRNA cancer vaccine intismeran autogene improves outcomes in solid tumors.
Phase 2 trial presented at ASCO annual conference shows that the personalized mRNA cancer vaccine intismeran autogene improves outcomes in solid tumors.
Reporting on June 4, 2026, noted that phase 2 trial presented at ASCO annual conference shows that the personalized mRNA cancer vaccine intismeran autogene improves outcomes in solid tumors.
Quantitative details referenced in the item include 2 , 2026 .
Phase 2 trial presented at ASCO annual conference shows that the personalized mRNA cancer vaccine intismeran autogene improves outcomes in solid tumors.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.medicalnewstoday.com/news